Document is current
Any future updates will be listed below
-
Authors
Khaddour, Karam https://orcid.org/0000-0001-6697-3516
Buchbinder, Elizabeth I.
- License Information
-
More Information
Article History
Accepted: 10 January 2025
First Online: 29 January 2025
Declarations
:
: E.B. discloses consultation as an advisory board member for Werewolf pharma, Merck, Iovance, Sanofi, Xilio, Novartis, and Instilbio, and receiving clinical trial support from Lilly, Novartis, Partners therapeutics, Genentech, and BVD. K.K. discloses no competing interest.
: There was no funding provided for this work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: K.K.: conception of the article, interpreting the relevant literature, writing original manuscript, creating figures, review and edits, and supervision. E.I.B.: conception of the article, review and editing, and supervision.
